During embryonic development, the aristaless-type homeodomain protein Alx3 is expressed in the forehead mesenchyme and contributes to the regulation of craniofacial development. In the adult, Alx3 is expressed in pancreatic islets where it participates in the control of glucose homoeostasis. In the present study, we investigated the transcriptional regulation of Alx3 gene expression in these two cell types. We found that the Alx3 promoter contains two E-box regulatory elements, named EB1 and EB2, that provide binding sites for the basic helix-loop-helix transcription factors Twist1, E47, USF (upstream stimulatory factor) 1 and USF2. In primary mouse embryonic mesenchymal cells isolated from the forehead, EB2 is bound by Twist1, whereas EB1 is bound by USF1 and USF2. Integrity of both EB1 and EB2 is required for Twist1-mediated transactivation of the Alx3 promoter, even though Twist1 does not bind to EB1, indicating that binding of USF1 and USF2 to this element is required for Twist1-dependent Alx3 promoter activity. In contrast, in pancreatic islet insulin-producing cells, the integrity of EB2 is not required for proximal promoter activity. The results of the present study indicate that USF1 and USF2 are important regulatory factors for Alx3 gene expression in different cell types, whereas Twist1 contributes to transcriptional transactivation in mesenchymal, but not in pancreatic, cells.
INTRODUCTION
Aristaless-like genes comprise a family of related genes encoding transcription factors characterized by the presence of a pairedtype homeodomain and a so-called aristaless domain [1] . Studies in mice have indicated that the homologous aristaless-like genes share overlapping patterns of expression during embryonic development, being more abundant in cells of the cranial mesenchyme, branchial arches, body wall mesoderm and limb buds [2, 3] .
From an evolutionary point of view, detailed studies carried out in several vertebrate species reveal the existence of a high degree of structural conservation and of similar spatial gene expression patterns [2, [4] [5] [6] , underscoring the prominent role of these genes in important developmental processes, such as formation of craniofacial structures. Indeed, genetic studies in humans have shown that some types of congenital craniofacial alterations, known as frontonasal dysplasias, are associated with mutations in the ALX1, ALX3 or ALX4 genes [7] [8] [9] .
The notion that aristaless-like genes play important developmental roles is further supported by the findings of altered craniofacial and limb morphogenesis associated with loss-offunction mutations in mice [10] [11] [12] [13] [14] . In the case of Alx3, studies in our laboratory demonstrated that lack of expression is associated with facial midline and cranial neural tube closure defects [15] . Importantly, the coincidental temporal and spatial pattern of expression of aristaless-like genes indicates the existence of overlapping or redundant functions and genetic interactions [2, [4] [5] [6] .
Independently of its functions during development, Alx3 is expressed in adult pancreatic islets, where its presence is necessary to maintain adequate levels of expression of genes that are important for the control of glucose homoeostasis [16] [17] [18] . Lack of expression of Alx3 in mice leads to islet cell dysfunction due to reduced insulin content in β-cells, increased apoptosis and decreased β-cell mass. As a consequence, Alx3-deficient mice exhibit impaired glucose homoeostasis that worsens as these animals get older [17, 18] . These data strongly suggest that Alx3 is indeed part of the pancreatic islet cell-specific transcriptional gene network required for ensuring adequate islet function on the systemic control of glucose homoeostasis.
As a component of a pancreatic islet gene network, as well as of a developmentally regulated gene network controlling craniofacial development, an important question that emerges in order to understand how expression of Alx3 is activated is, what are the molecular mechanisms that regulate its expression at the transcriptional level? In the present study, we have addressed this question and found that the proximal promoter of Alx3 binds different bHLH (basic helix-loop-helix) transcription factors.
MATERIALS AND METHODS

Cell culture
RC2.E10 cells derive from embryonic neural tissue [19] and were used as a reference system because they constitutively express Alx3 [20] . These cells were cultured at 33
• C in RPMI 1640 medium, whereas HeLa, NIH 3T3, COS7 and MIN6 cells were cultured at 37
• C in DMEM (Dulbecco's modified Eagle's medium). Further details are provided in the Supplementary Online Data (at http://www.biochemj.org/bj/450/bj4500199add.htm).
Primary MEM cells were isolated from the forehead mesenchyme of CD1 mouse embryos obtained at 10.5 days of gestation from time-pregnant females. This gestation time was chosen to maximize the number of cells co-expressing Alx3 and Twist1. Embryos were placed in PBS under sterile conditions and a piece including the most rostroventral part of the forehead and the first and second branchial arches was carefully dissected from the rest of the head and developing telencephalon. Pieces from an entire litter were pooled and were incubated with trypsin at 37
• C for 5-10 min. Cells were then dispersed by gentle pipetting and plated into 35 mm dishes containing DMEM and 20 % FBS (fetal bovine serum). After an overnight incubation, cells were washed and incubated in the presence of 10 % FBS until confluent. After this, cells were split a maximum of three times. Animal experimentation was carried out according to the appropriate Institutional guidelines.
Plasmids and transfections
The luciferase reporter plasmid Alx202Luc contains a fragment of the mouse Alx3 promoter spanning nucleotides −202 to +88 relative to the transcription initiation site [15] . Details of mutations in the two E-box elements EB1 and EB2 located in Alx202Luc are provided in the Supplementary Online Data.
Transfections were carried out using Lipofectamine TM (see the Supplementary Online Data for details). Data are presented as means + − S.E.M. for three to seven independent experiments each carried out in duplicate.
EMSAs (electrophoretic mobility-shift assays)
EMSAs were carried out using nuclear protein extracts exactly as described previously [18] . The sequences of the oligonucleotides used are shown in Supplementary Table S1 (at http://www. biochemj.org/bj/450/bj4500199add.htm). For supershift experiments, nuclear extracts were pre-incubated with specific antibodies before the addition of the labelled probes as indicated (see the Supplementary Online Data).
ChIP (chromatin immunoprecipitation) assays
ChIP assays were carried out as described previously [18] , setting aside 1 % of the original sample as the input. PCR was performed using oligonucleotide primers that amplify a fragment of the Alx3 gene spanning nucleotides −202 to +88 relative to the transcription initiation site. As a negative control, PCR was carried out using oligonucleotide primers that amplify a fragment of a distal region of the promoter of the Alx3 gene spanning nucleotides −1506 to −967.
For transient ChIP assays, MIN6 or MEM cells plated into 100 mm dishes were transfected with 2 or 5 μg of Alx202Luc or Alx202EB1mLuc as indicated. After 48 h of incubation, cells were fixed with formaldehyde and ChIP assays were carried out as described previously [18] . For PCR, the same forward primer indicated above was used, but an oligonucleotide that specifically anneals to the pGL3 backbone plasmid was used as a reverse primer.
PCR products were run on a 1 % agarose gel, stained and photographed. For primer sequences and PCR conditions see the Supplementary Online Data.
RNAi (RNA interference)
RNAi was carried out using double-stranded RNA duplexes validated in previous studies [24] [25] [26] . A Stealth TM RNAi negativecontrol duplex (Invitrogen) was used. Cells were transfected by adding a mixture containing 5 μl of Lipofectamine TM 2000 (Invitrogen), 500 μl of OptiMEM (Invitrogen) and 200 nM siRNA (small interfering RNA). Cells were harvested 72 h after transfection, and Twist1 silencing and Alx3 expression were tested by quantitative RT (reverse transcription)-PCR and Western blot analysis (see the Supplementary Online Data for details).
RT-PCR
Total RNA was extracted using TriReagent (Molecular Cell Center). RNA (5 μg) was primed with poly-(dT) 15 and incubated with avian myeloblastosis virus reverse transcriptase to synthesize cDNA. The sequences of primers used for PCR amplifications are shown in Supplementary Table S2 (at http://www.biochemj. org/bj/450/bj4500199add.htm). PCR conditions to amplify Alx3 and Twist1 were: 95
• C for 5 min, followed by 30 cycles of 95
• C for 30 s, 55
• C for 30 s, and 72
• C for 30 s, after which a 5 min incubation at 72
• C followed. PCR conditions for actin were identical, with the exception that only 25 cycles were used.
Western blot analysis
Lysates from cells growing in 60 mm dishes were prepared and proteins were resolved by SDS/PAGE (10 % gel) and blotted on to BioTrace PVDF membranes (Pall Corporation). For experiments described in Figure 5 (B), Alx3 immunoreactivity was detected using a previously described rabbit polyclonal primary antiserum [20] at a 1:5000 dilution. For experiments described in Figures 5(C) and 5(I), Alx3 was detected with a rabbit antiserum that had been raised against a GST (glutathione transferase) fusion protein named GST-Alx3 C which includes the Nterminal region of Alx3, but excludes both the homeodomain and the C-terminus. This antiserum was purified by affinity chromatography using GST-Alx3 C bound to glutathioneSepharose beads. Specificity was confirmed by Western blot analysis using recombinant Alx3 and cellular lysates. Twist1, TFII-I (transcription factor II-I), USF1 and USF2 were detected using commercial antibodies (see the Supplementary Online Data). Immunoreactive bands were visualized using an ECL (enhanced chemiluminescence) detection system (Immobilon Western Chemiluminescent HRP Substrate, Millipore).
Immunoprecipitation
Nuclear proteins were prepared as described previously [18] and were incubated overnight at 4
• C with specific antibodies or with control IgG (see the Supplementary Online Data). Protein A-Sepharose was added for another 2 h. After this, the samples were centrifuged (9600 g for 1 min at 22
• C), washed and resolved by SDS/PAGE (12 % gel). Proteins were blotted on to a PVDF membrane (Pall Corporation), and Twist1 or TFII-I immunoreactivities were detected by Western blot analysis. . EB1/2m denotes the mutation of both EB1 and EB2 boxes. Transfection with pGL3 was used as a negative control. *P < 0.05 and **P < 0.01 (Student's t test).
RESULTS
The presence of two E-box regulatory elements in the proximal promoter of Alx3
Our previous studies indicated that a region of the mouse Alx3 promoter spanning nucleotides −202 to +88 relative to the transcription initiation site is sufficient to confer full transcriptional activity in RC2.E10 cells [15] . Inspection of the sequence of this region revealed the existence of two putative E-box control elements containing the consensus sequence CANNTG that could be recognized by bHLH proteins [27] . These were named EB1 (nucleotides −42 to −37) and EB2 (nucleotides −127 to −122) ( Figure 1A ). To determine whether these elements were functionally important for Alx3 promoter activity, we transfected RC2.E10 cells with plasmids that incorporated mutations in each one of the E-box control elements. We found that mutations in either EB1 or EB2 completely inhibited luciferase activity ( Figure 1B ), suggesting that both sites are important for transactivation of the Alx3 gene.
Since Alx3 is expressed in the murine embryonic head mesenchyme during development, as well as in adult pancreatic islets, we carried out similar experiments in primary cultured MEM cells and in pancreatic islet insulin-producing MIN6 cells [28] . Expression of Alx3 in MIN6 cells has been demonstrated previously [18] and was confirmed in the present study (see Figure 5C ). Similar to what was found in RC2.E10 cells, we observed that the integrity of EB1 and EB2 is important for the maintenance of full transcriptional activity of the Alx3 proximal promoter in transfected primary MEM cells ( Figure 1C ). In contrast, we found that, contrary to what we had observed in RC2.E10 and primary MEM cells, only EB1 appeared to be important for promoter activity in pancreatic MIN6 cells, because mutation of the EB2 site did not significantly alter Alx3 promoter activity in these cells ( Figure 1D ). These results indicate that EB1 is a potentially important regulator of Alx3 expression in different types of cells, and therefore we initially focused our attention on the identification of transcription factors that bind to this element.
USF1 and USF2 specifically bind to EB1
Direct binding of nuclear proteins to EB1 and/or EB2 was tested by EMSA. Sequence-specific DNA-protein complexes bound to the EB1 site were observed with nuclear extracts from all cells tested ( Figure 2 ). Of note, the protein complexes bound to the EB1 probe could not be competed with an excess of non-radioactive EB2 oligonucleotide (Figure 2 ), lending support to the notion that the proteins which recognize EB1 are different from the proteins that recognize EB2. This was further indicated by the finding that specific DNA-protein complexes bound to the EB2 site were observed with nuclear extracts from RC2.E10 and MEM cells (Figures 2A and 2B ), but not from pancreatic MIN6 cells ( Figure 2C ).
Inspection of the DNA sequence of the EB1 element revealed that it fits the preferred site for binding by the bHLH transcription factors USF1 and USF2 [29] . Expression of USF1 and USF2 in RC2.E10, MIN6 and primary MEM cells was confirmed by Western blot analysis ( Figure 3A ). We carried out ChIP assays using anti-USF1 or anti-USF2 antibodies, and these experiments indicated that both of these transcription factors bind to the proximal region of the Alx3 promoter in all cell types tested in vivo ( Figure 3B ). In addition, EMSAs carried out in the presence of these antibodies indicated that both proteins recognize the EB1 probe, but not the EB2 probe ( Figures 3C-3E ). Thus these experiments indicate that the EB1 site of the Alx3 promoter is occupied by USF1 and USF2.
To evaluate the transcriptional transactivation activity of USF proteins on the Alx3 promoter, we co-transfected RC2.E10 cells with the Alx202Luc reporter and with expression vectors encoding USF1 or USF2. We found that expression of each USF protein did not significantly modify luciferase activity ( Figure 4A ), suggesting that, in these cells, USF proteins are bound to the Alx3 promoter in saturating amounts. Thus we sought to confirm a possible involvement of USF transcription factors in the regulation of Alx3 gene expression by co-transfecting Alx202Luc with an expression plasmid encoding a dominantnegative mutant of USF. In this case, we found that the dominant-negative inhibitor of USF significantly decreased the Alx202Luc reporter activity in RC2.E10 cells ( Figure 4A ), a result that we also observed in the case of similarly transfected primary MEM and MIN6 cells ( Figures 4B and 4C ). Thus these data indicate that USF1 and/or USF2 mediate Alx3 promoter activation in these three types of cells.
Next, we tested the capability of USF proteins to transactivate the Alx3 promoter using HeLa cells. We found that cotransfections of the Alx202Luc reporter with the USF1 or USF2 expression vectors resulted in increased luciferase activity, but this did not increase further when both transcription factors were co-expressed concomitantly ( Figure 4D ). USF-dependent transcriptional activity was abolished by mutation of the EB1 site, but was not significantly altered by mutation of the EB2 site, further supporting the notion that USF1 and USF2 transactivate the Alx3 promoter by binding specifically to the EB1 box ( Figure 4D ).
EB2 is recognized by Twist1 in MEM cells
The experiments described above indicate that the EB1 site is involved in the regulation of the Alx3 promoter by binding USF1 and USF2 transcription factors in all cells tested. Thus we next . Nuclear extracts were incubated in the absence (−) or presence of competing oligonucleotides of identical probe sequence (EB1 or EB2) or in the presence of mutated EB1 (EB1m) or EB2 (EB2m) oligonucleotides, each used at the indicated fold molar excess. Specific complexes are indicated with arrowheads. Note that addition of the EB2 oligonucleotide does not disturb the complex bound to the EB1 probe, and the absence of specific DNA-protein complexes when the EB2 probe was used with nuclear extracts of MIN6 cells (C). Asterisks denote non-specific DNA-protein complexes. or MEM (E) cells to oligonucleotide probes corresponding to the EB1 or EB2 boxes. Binding reactions were carried out in the absence (−) or presence of specific anti-USF1 or anti-USF2 antibodies or control IgG. Note that the addition of anti-USF antibodies only disturbs the complexes bound to the EB1 probe, but not those bound to the EB2 probe (C).
focused our attention on the identification of the transcription factor that may regulate Alx3 expression from the EB2 site in embryonic mesenchyme cells. To this end, we searched the literature for bHLH transcription factors that could be related to Alx3 expression during mouse development. We noticed that the gene encoding the bHLH protein Twist1 showed a coincidental temporal and spatial pattern of expression in the murine embryonic head mesenchyme [30] . Thus we carried out experiments using MEM cells to find out whether Twist1 regulates Alx3 promoter activity.
We confirmed the expression of Twist1 and Alx3 in these cells by RT-PCR and Western blot analysis ( Figures 5A and 5B ). In contrast, Twist1 was undetectable in Alx3-expressing MIN6 cells ( Figures 5A and 5C ). To determine whether Twist1 binds to the endogenous Alx3 gene in the context of native chromatin in vivo, we carried out ChIP assays. The anti-Twist1 antiserum specifically immunoprecipitated a fragment of chromatin corresponding to the proximal region of the Alx3 promoter from samples obtained either from RC2.E10 or from primary MEM cells ( Figures 5D  and 5E ). Since Twist1 can bind DNA forming a heterodimer with the bHLH protein E47 [31] , we carried out additional ChIP assays and determined that this transcription factor also recognizes this region of the Alx3 promoter ( Figure 5D ). ChIP specificity was tested on a different region of the promoter of the Alx3 gene spanning nucleotides −1506 to −967 relative to the transcription initiation site, which was not amplified in samples obtained after immunoprecipitation with the anti-Twist1 antiserum ( Figure 5D ). The occurrence of a direct interaction between Twist1 and E47 in MEM cells in vivo was tested by immunoprecipitation using the E47 antiserum, followed by Western blot analysis with a specific anti-Twist1 antibody. The detection of a band corresponding to Twist1 in samples immunoprecipitated with the anti-E47 antiserum, but not in those immunoprecipitated with control IgG, confirmed the Twist1-E47 interaction in MEM cells ( Figure 5F ). Thus these experiments indicate that Twist1 occupies the proximal Alx3 promoter in vivo.
Direct binding of Twist1 to EB1 and/or EB2 was tested by EMSA in the presence of a specific anti-Twist1 antiserum. This did not disturb the complex bound to EB1 ( Figure 5G ). In contrast, consistent with the results from the ChIP experiments mentioned above, the addition of the anti-Twist1 antiserum detected Twist1 binding to the EB2 probe with nuclear extracts of either RC2.E10 or primary MEM cells ( Figure 5G ). Thus these experiments indicate that Twist1 binds specifically to EB2, but not to EB1.
The importance of Twist1 for the regulation of the expression of the native Alx3 gene was investigated in primary MEM and RC2.E10 cells by silencing of Twist1 using siRNA. In both cases, transfection of cells with specific Twist1-targeted siRNA caused a significant decrease in Twist1 mRNA levels ( Figure 5H ) which correlated with a decrease in Twist1 protein levels ( Figure 5I ). Western blot analysis showed that Twist1 silencing resulted in a significant reduction in Alx3 expression ( Figure 5I In contrast, the intensity of USF1 and USF2 immunoreactive bands was not altered in cells transfected with the Twist1 siRNA ( Figure 5I ), indicating that the reduction in Alx3 levels was specifically due to silencing of Twist1.
Twist1-mediated transactivation requires the integrity of both EB1 and EB2
To investigate whether Twist1 transactivates the Alx3 promoter, we co-transfected RC2.E10 and MEM cells with the Alx202Luc reporter and with an expression vector encoding Twist1. We found that Twist1 did not modify basal luciferase activity, even when cotransfected with an expression vector encoding E47 ( Figure 6A ), suggesting that, in these two types of cells, Twist1 is bound to the Alx3 promoter in saturating amounts or that the Alx3 promoter displays full activity constitutively. MIN6 cells were similarly transfected, but no effect of Twist1 and E47 on Alx202Luc reporter activity was detected (results not shown).
We then carried out similar experiments in HeLa cells, in which Alx3 is not constitutively expressed [18] . In this case, basal luciferase activity elicited by Alx202Luc was close to background levels, indicating that the Alx3 promoter is relatively inactive in HeLa cells ( Figure 6B ). Co-transfection with expression vectors encoding either E47 or Twist1 did not significantly modify luciferase activity, but when both transcription factors were coexpressed a significant increase was observed ( Figure 6B ). This increased activity was dependent on the integrity of the EB2 element, because the combination of E47 and Twist1 did not have any effect when this site was mutated ( Figure 6B) , consistent with the EMSA data described above showing Twist1 binding to this site. Surprisingly, however, we observed that mutation of the EB1 element, which does not bind Twist1, also prevented transactivation elicited by co-expression of E47 and Twist1 ( Figure 6B ), suggesting that the presence of USF1 and USF2 bound to EB1 is required for Twist1-dependent activity from EB2.
To test this idea directly, we carried out additional transfection experiments in HeLa cells. We found that the Alx3 promoter activity elicited by the concomitant expression of Twist1 and E47 was not enhanced further in the presence of USF1 and/or USF2 ( Figure 7A ), indicating that the Twist1-E47 heterodimer does not engage in synergistic interactions with USF transcription factors. On the other hand, we observed that the Alx202Luc reporter activity elicited by Twist1 and E47 was completely inhibited in the presence of a dominant-negative inhibitor of USF ( Figure 7B ). Thus, taken together these experiments support the idea that the transcriptional transactivation of Alx3 by Twist1-E47 from the EB2 site requires the presence of USF transcription factors bound to EB1.
USF1 interacts with TFII-I on the EB1 site
The distance between EB1 and EB2 (79 bp) makes it unlikely that Twist1 interacts directly with USF1 or USF2. However, due to the proximity of EB1 to the transcription initiation site, we argued that it would be possible that USF transcription factors may play a permissive role by interacting directly with components of the basic transcriptional machinery. To test this notion, we carried out immunoprecipitations from primary MEM or MIN6 cells using USF1-or USF2-specific antibodies, and tested for the presence of interacting TFII-I [32, 33] in these samples by Western blot analysis. We found that in these cells TFII-I interacts directly with USF1, but not with USF2 ( Figure 8A ). The presence of TFII-I in the protein complexes bound to EB1 was tested by EMSA. We found that the addition of a specific anti-TFII-I antibody to the binding reactions disturbed the formation of the complexes bound to EB1 ( Figure 8B ). In addition, ChIP assays confirmed the presence of TFII-I bound to the proximal region of the native Alx3 promoter in vivo ( Figure 8C ). Finally, taken the above results into account, we argued that failure of USF transcription factors to bind to EB1 could prevent assembly of TFII-I on the Alx3 promoter. We tested this hypothesis by transient ChIP assays in cells transfected with the plasmids Alx202Luc, which includes an intact EB1 site, or Alx202EB1mutLuc, in which the EB1 site has been mutated. These experiments showed that TFII-I occupies the Alx3 promoter, but mutation of the EB1 site prevented binding of TFII-I ( Figure 8D ).
DISCUSSION
In the present study we provide direct evidence in support of the notion that expression of Alx3 in embryonic mesenchyme cells is directly regulated by Twist1 [34] . We identified EB2, a specific E-box regulatory element located in the proximal promoter of Alx3, as a binding site for Twist1. Importantly, we found that transcriptional transactivation of the Alx3 promoter by Twist1 requires the binding of USF transcription factors to another E-box site known as EB1, located in relatively close proximity to EB2. This configuration appears to operate in a cell-type-restricted manner, because EB2 does not apparently contribute significantly to transcriptional regulation of Alx3 expression in pancreatic islet insulin-producing cells. Nonetheless, expression of Alx3 in pancreatic islet cells requires binding of USF transcription factors to EB1.
Regulation of Alx3 transcription by Twist1 in embryonic mesenchyme cells
Indirect evidence suggests that Twist1 may participate in the transcriptional mechanisms that regulate the expression of . In this case, luciferase reporters incorporating mutations in the EB1 (EB1m) or EB2 (EB2m) sites were also used. In all cases, the total amount of transfected DNA was kept constant by adding the corresponding empty vector. Transfection with pGL3 was used as a negative control. *P < 0.05 relative to the values of Alx202Luc alone (Student's t test).
aristaless-like genes [34] . It has been shown that defects in the closure of the cranial neural tube of Alx3-and Cart1-null mouse embryos, due to increased apoptosis in the cranial mesenchyme that compromises its expansion [10, 15] , are similar to those found in Twist1-deficient mice [35] [36] [37] . In addition, during embryonic development in mice, Twist1 is expressed in the head mesenchyme, branchial arches and limb buds at a time that coincides with expression of aristaless-like genes [30] . Indeed, in Twist1-deficient embryos the expression of Alx3, Alx4 and Cart1 is down-regulated both in the forehead mesenchyme [36, 37] and in the developing limb buds [38, 39] . Thus the results of the present study provide a mechanistic explanation for the previous observations that the phenotypic features observed in Twist1-deficient embryos [35] [36] [37] 39] can be partially recapitulated by loss-of-function mutations in aristalesslike genes [10, 11, 14, 15] . In addition, they provide a mechanistic interpretation to the previously observed down-regulation of Alx3 expression associated with Twist1-deficiency in embryonic tissues [36] [37] [38] .
A direct interaction between Twist1 and the promoters of aristaless-like genes also provides a mechanistic interpretation for some of the similarities of craniofacial defects observed in human patients with mutations in these genes. Mutations in the TWIST1 Histograms represent the relative levels of luciferase activity elicited in HeLa cells co-transfected with the reporter plasmid Alx202Luc and expression plasmids encoding USF1, USF2, a dominant-negative inhibitor (DN) of these transcription factors, Twist1 and E47 as indicated. In (A) the data show that the luciferase activity elicited by the combination of Twist1 and E47 is not significantly enhanced in the presence of USF1 or/and USF2. In (B), the presence of the dominant-negative inhibitor inhibits transactivation by USF1 and/or USF2, used as controls, as well as by Twist1-E47. In all cases, the total amount of transfected DNA was kept constant by adding the corresponding empty vector. n.s., non-significant; *P < 0.05 (Student's t test), n = 4.
gene are the cause of the Saethre-Chotzen syndrome [40, 41] , which includes alterations such as craniosynostosis, abnormal nasal morphogenesis, cleft palate and hypertelorism. Similar defects, including alterations in the closure of cranial sutures, can also be observed in frontonasal dysplasias caused by mutations in the ALX3 or ALX4 genes [7, 8, 42] .
In mouse embryos, Twist1 deficiency is associated with decreased expression of Alx3, Alx4 and Cart1 in the craniofacial mesenchyme [36, 37] . However, recent phylogenetic studies indicate that there are subtle, but important, differences derived from the observation that Alx3 is more closely related to Cart1 than to Alx4 [6] . In this context, it has been found that in restricted areas of the developing facial region of Twist1-deficient embryos, such as the distal part of the mandible, Alx3 expression is inhibited but Alx4 expression is retained [37] . This clearly indicates that additional Twist1-independent transcriptional mechanisms regulate the expression of Alx4, despite the existence of at least two potential E-box regulatory elements identified by analysis of the sequence provided by the Ensembl database (http://www.ensembl.org) within the mouse Alx4 proximal promoter. Twist1 can bind DNA either as a homodimer or as a heterodimer with a different bHLH transcription factor and, depending on the dimerization partner, its activity may change from a repressor to an activator [43] [44] [45] [46] . The results of the present study indicate that binding of Twist1 to the Alx3 promoter with a homodimeric conformation is unlikely, because overexpression of Twist1 alone did not have any effect on transfected Alx3-luciferase reporter activity. A more likely possibility supported by our transfection, immunoprecipitation and ChIP data is that Twist1 binds to the EB2 element as a heterodimer with the E2A bHLH protein E47. Nonetheless, we cannot rule out the possibility that additional or different bHLH transcription factors may interact with Twist1 on the Alx3 promoter.
We found that Alx3 transactivation by Twist1 bound to EB2 requires the binding of USF transcription factors to EB1, which is located 79 bp away. A similar situation has been suggested to occur in the case of Twist1-mediated transactivation of the GLI1 gene [47] . The distance between EB1 and EB2 makes it unlikely that Twist1 interacts directly with USF1 or USF2, although interactions of Twist1 and USF1/2 with another protein tethered to the transcription complex cannot be ruled out.
Interaction of USF1 with TFII-I
The Alx3 promoter does not have a canonical TATA box. Instead, the motif CCAGCATT, located at position −24 to −17 from the transcription initiation site assigned by the Ensembl database, resembles a putative initiator site (consensus YYANT/AYY) [48] and is located downstream from EB1 separated by just 12 bp. USF transcription factors can regulate transcriptional activity from an initiator element [49, 50] , probably via direct interactions with components of the protein complex assembled on the initiator element such as TFII-I [32, 33] . The results of the present study indicate that TFII-I interacts with USF1 in MEM and MIN6 cells, and that the integrity of EB1 is required for TFII-I binding to the Alx3 promoter. TFII-I, whose structure is characterized by the presence of one basic motif and six additional HLH repeats, can bind to E-box elements in association with USF proteins [51] . The results of the present study favour a configuration such that an USF1-TFII-I heterodimer bound to the EB1 element could play a permissive role on Alx3 transcription, perhaps coupling the activity of transcription factors bound upstream on the promoter with the basic transcriptional machinery. In the case of MEM cells, this would explain why Twist1 bound to the EB2 site is transcriptionally inactive when the EB1 site is mutated. In the case of pancreatic islet cells, work is ongoing in our laboratory to identify additional regulatory elements and transcription factors acting on the Alx3 promoter upstream from the EB2 site.
Regulation of Alx3 transcription by USFs, but not Twist1, in pancreatic islet cells
The results of the present study suggest that EB2 is not a critical cis-regulatory element for expression of Alx3 in pancreatic islet cells. This is not surprising in light of the observation that Twist1 is, if anything, only weakly expressed in the pancreas [52] . Even when overexpressed in MIN6 cells, Twist1 and E47 did not stimulate Alx3 promoter activity. Lack of activity of ectopically expressed Twist1 in MIN6 cells could be due to a number of reasons, although it is known that in these pancreatic cells heterodimeric bHLH proteins may require co-operative interactions with other transcription factors in order to exert transactivation activity [18] .
In contrast, Alx3 promoter activity in pancreatic islet cells requires binding of USFs to the EB1 site. USF1 and USF2 have been found to be important for the regulation of different pancreatic islet genes involved in the control of glucose metabolism [53, 54] , as well as in that of Pdx1 (pancreatic and duodenal homeobox 1) [29] , a key regulator of pancreatic development and function whose defect is associated with maturity onset diabetes of the young [55] . Indeed, the USF1 locus in humans has been found to be associated with increased risk to develop Type 2 diabetes, although it cannot be ruled out that this association may be more related to lipid than to glucose metabolic defects [56] . In any case, the finding that USF1 and USF2 transactivate the Alx3 promoter is important because, as we have shown in previous studies [17, 18] , expression of Alx3 is required for maintaining adequate levels of expression of pancreatic islet genes including insulin, and Alx3 loss-of-function in mice results in a progressive decrease in islet cell mass and alterations in glucose homoeostasis leading to diabetes. A more in-depth characterization of the regulation of Alx3 by USF1 and USF2 in pancreatic islets is currently being carried out in our laboratory.
In conclusion, the results of the present study strongly support an involvement of USF transcription factors in the regulation of the expression of the Alx3 gene. In addition, Twist1 contributes to expression of Alx3 in embryonic mesenchymal cells, but not in pancreatic islet cells.
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SUPPLEMENTARY ONLINE
MATERIALS AND METHODS
Cell culture
All cells were maintained in the presence of 10 % FBS, with the exception of MIN6 cells, which were cultured in the presence of 15 % FBS and 2-mercaptoethanol (70 μM) and were not used after reaching 35 passages. Streptomycin (10 μg/ml), penicillin (100 units/ml) and fungizone (2.5 μg/ml) were added to cultures in all cases.
Plasmid mutagenesis
The two E-box elements EB1 and EB2 in Alx202Luc were mutated by oligonucleotide-directed mutagenesis using Pfu Turbo DNA polymerase from a QuikChange ® II Site-Directed Mutagenesis kit (Stratagene) and the following primers (sense strand): EB1 mutant, 5 -CCCGCACGGGGCCGCCGCGGACG-TGGATGGTTCC-3 ; and EB2 mutant, 5 -CTTCCCTCTCTTCT-CTTCCCGCGGCTTGTGATACCAGACTCG-3 . This generated the plasmids Alx202EB1mLuc and Alx202EB2mLuc respectively.
Transfections MEM, RC2.E10, HeLa or MIN6 cells were seeded into 24-well plates at densities of 7×10 4 , 6×10 4 , 9×10 4 and 10 5 cells/well respectively. After an overnight incubation, the medium was removed and cells were transfected for 4 h with Lipofectamine TM (Invitrogen), using 0.5 μg of luciferase reporter plasmid and 0.05 μg of pRL-TK-Renilla. When required, 0.25 μg of expression plasmids or the corresponding empty vectors were used. In all cases, the total amount of DNA was kept constant.
Luciferase and Renilla activities were measured using a commercial Dual Luciferase Assay kit (Promega) 48 h after transfection. The Rous sarcoma virus enhancer reporter plasmid RSV-Luc was used as an independent standard for normalization, and efficiencies were corrected by using the Renilla luciferase assay system (Promega).
Commercial antibodies used
For supershift experiments (EMSAs) the antibodies used were anti-Twist1 (catalogue number sc-6070), anti-USF1 (catalogue number sc-229), anti-USF2 (catalogue number sc-862), anti-TFII-I (catalogue number sc-9943) and control IgG, all from Santa Cruz Biotechnology. For chromatin or standard immunoprecipitation assays the antibodies used were anti-USF1 (catalogue number sc-229), anti-USF2 (catalogue number sc-862), anti-Twist (catalogue number sc-6070), anti-E47 (catalogue number sc-763) and control IgG, all from Santa Cruz Biotechnology. For Western blots the primary antibodies used were anti-Twist (catalogue number sc-6070, 1:2000 dilution), anti-TFII-I (catalogue number sc-9943, 1:1000 dilution), anti-USF1 (catalogue number sc-229, 1:1000 dilution) and anti-USF2 (catalogue number sc-862, 1:1000 dilution), all from Santa Cruz Biotechnology, and anti-actin (catalogue number A5441, 1:10000 dilution), from Sigma. The secondary antibodies used were horseradish-peroxidaseconjugated goat anti-rabbit (Bio-Rad Laboratories), donkey antigoat (Jackson ImmunoResearch) or donkey anti-mouse (Bio-Rad Laboratories), all used at a 1:20 000 dilution.
Oligonucleotides and PCR conditions used in ChIP assays
For Alx3 ( − 202 to + 88), the forward primer was 5 -CAC-TCGAGGAGCCAAGGACTCACCCGAC-3 and the reverse primer was 5 -CAAAGCTTTGTGAGCCAAGGGGGAGGGA-3 . PCR conditions were 95
• C for 5 min, followed by 35 cycles of 95
• C for 30 s, 65
• C for 1 min, after which there was a 5 min incubation at 72
• C. For Alx3 ( − 1506 to − 967), the forward primer was 5 -CACTCGAGGAT-TAGATGCCCTGAAATGA-3 and the reverse primer was 5 -TTATATTTTTAGGACCCCTGGAGATTAG-3 . PCR conditions were 95
• C for 5 min, followed by 30 cycles of 94 • C for 30 s, 52
• C for 30 s, followed by a 5 min incubation at 72
• C. For transfected Alx202Luc or Alx202EB1mLuc, the forward primer was 5 -CACTCGAGGAGCCAAGGACTCACC-CGAC-3 and the reverse primer was 5 -TGTGAGCCAAGGG-GGAGGGA-3 .
PCR conditions were 95 • C for 5 min, followed by 30 cycles of 94
• C for 15 s, 57
• C for 15 s, and 72
• C for 15 s, followed by a 5 min incubation at 72
• C.
RNAi
The sequence of the custom siRNA duplex (Stealth TM RNAi system, Invitrogen) used was (only the sense strand is indicated) AGCUGAGCAAGAUUCAGACCCUCAA. Transfection efficiency was assessed by a fluorescein-labelled siRNA (Invitrogen) and estimated to be greater than 90 %.
Quantitative RT-PCR analysis was carried out with total RNA extracted using the Illustra RNAspin kit (GE Healthcare). SYBR Green detection was used with Power SYBR Green PCR Master Mix (Applied Biosystems) and the primers 5 -GCTCAGCTACGCCTTCTCC-3 (forward) and 5 -CCTTCTC TGGAAACAATGACATC-3 (reverse). PCRs were performed in triplicate in a 7900HT fast real-time PCR system (Applied Biosystems), and values were normalized to Gapdh mRNA levels. 
